Pascale Witz Joins Augustine Therapeutics as Board Chair
Augustine Therapeutics NV is thrilled to welcome Pascale Witz as the new Chair of its Board of Directors. With a robust background spanning over three decades in the life sciences sector, Witz arrives during a transformative period for Augustine, which is poised to advance its clinical-stage initiatives. Her appointment is expected to play a key role in steering the company towards its ambitious goals.
A New Era for Augustine Therapeutics
As Augustine embarks on its journey to bring innovative treatments for neuromuscular, neurodegenerative, and cardio-metabolic conditions to the market, the expertise that Witz brings will be invaluable. Previously occupying prominent roles such as Executive Vice President at Sanofi and CEO of GE Pharmaceutical Diagnostics, Witz has consistently demonstrated exceptional strategic leadership and operational excellence.
Commitment to Innovative Treatments
Augustine has made significant strides with its innovative approach targeting the inhibition of the HDAC6 enzyme. The company aims to develop groundbreaking therapies aimed at diseases that currently lack effective treatment options. Witz’s vast experience in the biotech industry will be essential as the company positions itself in the clinical stage, gearing up for potential market breakthroughs.
Strategic Vision for Growth
Witz expressed her enthusiasm about joining Augustine at a critical juncture for the company. Following a successful funding round that raised €78 million / $85 million, her leadership will focus on harnessing the potential of Augustine’s therapies. The company’s HDAC6 inhibitors are seen as pivotal in treating challenging conditions, and Witz’s insights will facilitate not just treatment advancements but overall organizational growth.
Leadership Experience that Matters
Witz has an impressive portfolio serving on boards of prominent pharmaceutical companies like Fresenius Medical Care AG and Regulus Therapeutics, providing governance and mentorship that extends beyond traditional roles. Her experience navigating the complexities of biotech acquisitions simultaneously adds depth to her new position at Augustine Therapeutics.
Recognizing Excellence
Pascale Witz is a noted figure in the industry, having earned accolades including recognition as one of Fortune’s Top 20 Most Powerful Women in EMEA. Her academic background includes a Master’s degree in Biochemistry from INSA Lyon and an MBA from INSEAD, alongside being decorated as a Chevalier de la Légion d’Honneur, which underscores her commitment to excellence in her field.
The Future is Bright for Augustine Therapeutics
With ongoing developments in HDAC6 inhibition, Augustine Therapeutics is well-equipped to step into its next phase under Witz's chairmanship. The focus remains on translating innovative science into effective medicine for patients struggling with neurodegenerative and cardio-metabolic diseases. Witz’s appointment marks a promising advancement as the company aims to maximize its research and operational capabilities.
Building Bridges Across the Industry
Pascale Witz is not just a new face on the board; she is viewed as a bridge connecting Augustine Therapeutics to broader networks and opportunities within the biotechnology community. Her established relationships and respect within the industry will help the company forge partnerships that can accelerate its mission and impact.
Frequently Asked Questions
Who is Pascale Witz?
Pascale Witz is the new Chair of the Board at Augustine Therapeutics, a seasoned executive with over 30 years in the life sciences industry.
What are Augustine Therapeutics' main areas of focus?
The company primarily focuses on developing therapies for neuromuscular, neurodegenerative, and cardio-metabolic conditions through pioneering HDAC6 inhibitors.
Why is the appointment of Witz considered significant?
Witz brings extensive strategic leadership experience, which is crucial as Augustine transitions into a clinical-stage company.
What was the recent achievement of Augustine Therapeutics?
Augustine successfully raised €78 million / $85 million in a Series A financing round to support its innovative therapies.
What recognition has Pascale Witz received in her career?
Witz has been recognized among Fortune’s Top 20 Most Powerful Women in EMEA and holds the title of Chevalier de la Légion d’Honneur, highlighting her outstanding contributions to her field.
